title: Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score.
abstract: IMS: To evaluate long-term outcome of tamsuolsin 0.2 mg for benign prostatic hyperplasia (BPH) patients using a new subjective assessment of patient-reported outcomes and the lower urinary tract symptoms (LUTS) outcome score (LOS) over a 48-week period.
  
  
  METHODS
  This study investigated the long-term outcomes of either well-responded or poorly responded patient group as defined by LOS at the period of 12 weeks after BPH treatment. Outcome parameters used in this study were the most bothersome symptoms, BPH K1-short form as well as International Prostate Symptom Score (IPSS), maximum flow rate (Qmax) and postvoiding residual urine volume at 24-, 36- and 48-week follow-up.
  
  
  RESULTS
  Of the 414 patients recruited initially, 310 (75.2%) were defined as the responders and 39 (9.5%) as the non-responders to the treatment at 12 weeks, which was stratified by LOS. In this long-term study, the differences in improvement rates of clinical parameters between responder and non-responder groups at 12 weeks of treatment were maintained over the period of 48 weeks. Among the responder patients, most (75.6%) chose continuous administrations of tamsulosin. Improvements in clinical parameters were maintained in this subgroup. It is noteworthy that the improvements in clinical parameters of the non-responder group were dismal despite switching to the other treatment modalities.
  
  
  CONCLUSIONS
  Long-term tamsulosin 0.2 mg for BPH patients is an effective treatment, both subjectively and objectively. Considering its integrative nature, LOS seemed to be one of the useful tools to predict the outcome after the management of LUTS.
authors.affiliation: Department of Urology, Korea University College of Medicine, Seoul, Korea.
authors.forename: S G
authors.initials: SG
authors.lastname: Kang
authors.forename: C H
authors.initials: CH
authors.lastname: Park
authors.forename: D K
authors.initials: DK
authors.lastname: Kim
authors.forename: J K
authors.initials: JK
authors.lastname: Park
authors.forename: S J
authors.initials: SJ
authors.lastname: Hong
authors.forename: B H
authors.initials: BH
authors.lastname: Chung
authors.forename: C-S
authors.initials: CS
authors.lastname: Kim
authors.forename: K-S
authors.initials: KS
authors.lastname: Lee
authors.forename: J C
authors.initials: JC
authors.lastname: Kim
authors.forename: J G
authors.initials: JG
authors.lastname: Lee
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D053448:Prostatism / Q000188:drug therapy* / Q000503:physiopathology; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects; D000077409:Tamsulosin; D016896:Treatment Outcome; D014563:Urodynamics / Q000502:physiology
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin